MBD3

Across TCGA pan-cancer cohorts, MBD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MBD3 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MBD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MBD3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MBD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.607	0.840	.002	38	view →
LUAD	DFS	Median	III,IV	0.972	0.547	.013	14	view →
PDAC	OS	Median	II,III,IV	0.530	0.291	.014	9	view →
COAD	DFS	Median	All	1.000	0.900	.042	6	view →
LSCC	OS	Quartile	All	0.972	0.802	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MBD3–HNSC (OS)

Open the HNSC breakdown →